Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Combination With CHOP for Previously Untreated T Cell Lymphoma
NCT06692452Phase 2Withdrawn
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of tazemetostat in peripheral T-cell lymphoma (PTCL) (2 arms). Primary endpoint: Complete Response Rate at 18 weeks. Planned start Dec 2024; status: withdrawn.
02
Drugs
tazemetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06692452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692452.